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SUMMARY
Therapy of advanced melanoma is changing dramat-
ically. Following mutational and biological subclas-
sification of this heterogeneous cancer, several tar-
geted and immune therapies were approved and
increased survival significantly. To facilitate further
advancements through pre-clinical in vivo modeling,
we have established 459 patient-derived xenografts
(PDX) and live tissue samples from 384 patients rep-
resenting the full spectrum of clinical, therapeutic,
mutational, and biological heterogeneity of mela-
noma. PDX have been characterized using targeted
sequencing and protein arrays and are clinically
annotated. This exhaustive live tissue resource in-
cludes PDX from 57 samples resistant to targeted
therapy, 61 samples from responders and non-re-
sponders to immune checkpoint blockade, and 31
samples from brain metastasis. Uveal, mucosal, and
acral subtypes are represented as well. We show ex-
amples of pre-clinical trials that highlight how the
PDX collection can be used to develop and optimize
precision therapies, biomarkers of response, and
the targeting of rare genetic subgroups.
INTRODUCTION
Therapeutic options for advanced melanoma have improved
from limited to approved kinase inhibitor and immune check-
point therapy. 5-year survival rates have nearly doubled (Men-
zies et al., 2015; Schadendorf et al., 2015). Precision medicine
and immune oncology aremajor areas of translational melanoma
research. The complex melanoma landscape needs improved
models reflecting all mutational and clinical subtypes. The UV
carcinogenic etiology of melanoma makes it one of the most
highly mutated cancers (Alexandrov et al., 2013). This highmuta-
tional burden may be the reason for the success of immune
checkpoint blockade (Callahan et al., 2016), but makes devel-
oping rational ‘‘precision’’ therapies challenging (Krepler et al.,
2016).
The Melanoma Cancer Genome Atlas (TCGA) includes
comprehensive molecular characterization of 333 non-acral
cutaneousmelanomas and is an important resource. It confirmed
Cell Reports 21, 1953–1967, November 14, 2017 ª 2017 The Authors. 1953
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the main mutational subgroups of BRAF, NRAS, NF1, and triple
wild-type (WT) and highlighted the distinct heterogeneity and
high mutational burden of melanoma (Cancer Genome Atlas,
2015). Subtypes not included in the TCGA but published else-
where are uveal (Van Raamsdonk et al., 2010), acral cutaneous
(Furney et al., 2014), andmucosal melanoma (Sheng et al., 2016).
Patient-derived xenografts (PDX) as xenotransplantation of
human tumors into athymic nude mice were first described by
Rygaard and Povlsen (1969). PDX are directly established from
patient tumors in immunodeficient mice and thus provide a
source of tumor tissue closely resembling the clinical lesion (Hi-
dalgo et al., 2014). Melanoma is uniquely suited to this approach
as even single cells are tumorigenic in vivo (Quintana et al., 2008).
Melanoma PDX were shown to accurately model the clinical dis-
ease and response to targeted therapy (Einarsdottir et al., 2014).
We have shown recently that PDX derived from BRAF-inhibitor-
relapsed patients and expanded on chronic therapy could be
used to identify effective second-line combination therapies
based on genomic and proteomic profiling (Krepler et al.,
2016). Whereas these studies demonstrate the feasibility of the
PDX approach, the melanoma TCGA and other studies (Arafeh
et al., 2015; Cancer Genome Atlas, 2015; Krauthammer et al.,
2015) highlight the pronounced heterogeneity of this cancer
type. Both concepts are combined here in an unparalleled
collection of 459 mutationally and clinically diverse melanoma
PDX and live frozen tissues, providing an exhaustive and testable
resource for the melanoma research field. This resource is highly
clinically annotated and includes rare body sites and sub-
types such as brain metastasis, uveal, mucosal, and acral mela-
noma, as well as pre- and post-therapy samples from targeted
inhibitor- and checkpoint-blockade-treated patients.
RESULTS
Establishment of Melanoma PDX
We have collected 694 melanoma samples for PDX generation
from eight institutions (Figure 1A). Fresh tumor samples were
either directly implantated within 24 hr subcutaneously (s.c.) in
NOD/SCID/IL-2Rgnull (NSG) mice or banked as cryopreserved
live tissue (Figure 1A). Keeping primary tissue in a live tumor
bank was a cost-effective alternative to fresh implantation but
depended on adequate amounts of tissue. Both approaches
successfully established PDX, and detailed methods are
included in the Experimental Procedures and in a standard oper-
ating procedures (SOP) handbook (Data S1).
Of the samples collected, 319 were established as PDX and
140 were banked as live primary tissue (Figure 1B), totaling
459 models from 384 different patients. Failure to establish a
PDX was due to sample contamination, unexpected death of a
primary recipient animal, receipt of non-viable samples, or
non-melanoma samples (Figure 1B). Thus, although the overall
success rate for establishing melanoma PDX was 62%, the
take rate corrected for these factors was 83% (Figure 1C). This
excluded primary uveal samples whose take rate was 11%.
Time to Tumor Growth and Tumor Growth Rate
Tumor samples were obtained from fine-needle aspirates (FNA),
corebiopsies,or surgical excisions.We foundnosignificantdiffer-
ence in latency (time from implantation to palpable tumor) and tu-
mor growth rates (time tomaximal tumor size) (Figures1Dand1E).
Very Small Cell Numbers Are Needed to Establish a
Melanoma PDX
Tissues from three patients were enzymatically digested, and
hematopoietic cells, red blood cells, and endothelial cells were
removed. We observed consistent tumor engraftment in mice
at 1,000, 100, 10, and 1 cell(s)/ mouse (Figure 1F). The latency
period was extended by up to 4 months indicating that a
follow-up of 6 months is optimal to achieve maximum engraft-
ment. Further, tumorigenicity did not significantly change when
sorting the cells for the cancer stem cell marker CD271 (Boiko
et al., 2010) (Figure 1G).
Patient Demographics Reflect the Clinical Spectrum of
the Disease
Patient ages ranged from 20 to 89 years, with a peak between
60 and 69 years (Figure 2A). Male patients were predominant,
likely representing our sampling bias for advanceddisease (Geller
et al., 2002) (Figure 2B). More than 80% of patients had stage IV
disease. The largest proportionof samples (68%)wasmetastases
from patients with non-acral cutaneous primaries (Figure 2C), but
we also included 59 unknown primary, 17mucosal, 15 acral cuta-
neous, and 10 uveal melanomas. Approximately 44% were s.c.
(Figure2D) and26% lymphnodemetastasis samples, since these
are often excised for diagnostic or therapeutic reasons. Remark-
ably, 23%weredistant organmetastates, includingbrain. Primary
melanomas represented 5%, although thesewere thick primaries
and the patients had often already developed stage III disease.
Our collection spanned several years, during which time ther-
apies for advanced melanoma have evolved. Samples therefore
reflect the standard of care and ongoing clinical trials at contrib-
uting centers, ranging from untreated to targeted therapy to im-
mune checkpoint blockade to combination therapies (Figure 2E).
Genomic Characterization and Clinical Annotation
The majority (n = 314, 68%) of PDX and tissues were analyzed for
genomic alterations usingmassively parallel sequencing of a 108-
gene-targeted panel. Genes included in this panel were selected
based on previously described mutations and copy number var-
iations in melanoma. A full list of included genes and an in-depth
analysis of mutational and copy number data of all PDX models
as well as additional melanoma cell lines (n = 488 total) are pro-
vided in a companion resource article (Garman et al., 2017 [this
issue of Cell Reports]). An additional 90 patients were annotated
by NGS targeted panels of 40–400 genes at their clinical institu-
tions, and we used these data to infer oncogenic driver mutation
status of PDX. Both datasets were combined to classify a total of
372 PDX or banked tissues into major mutational subgroups.
Half (55%) of all analyzed samples wereBRAF hotspotmutant,
20% NRAS mutant, 7% NF1 mutant, 2% KIT, 1.4% GNAQ/
GNA11, and 18% WT (Figure 3A; Data S2). These results corre-
late with themelanoma TCGA data (Cancer GenomeAtlas, 2015)
and other published large-scale sequencing studies (Arafeh
et al., 2015; Hodis et al., 2012; Krauthammer et al., 2015).
Thirty-seven of theBRAF hotspot mutation PDXwere from pa-
tients progressed on a BRAF inhibitor (12 previously published in
1954 Cell Reports 21, 1953–1967, November 14, 2017
Figure 1. Establishment and Biology of PDX Models
(A) A total of 694 melanoma tissue samples from naive, pre-, on-, or post-therapy time points receiving targeted kinase inhibitors (TT) or immune checkpoint
inhibitors (IT) were used to generate PDX and/or were banked as live tissue.
(B) Success rate of establishing a tumor graft (green), banking of live tissue with the potential of establishing a PDX or establishment in progress (blue), no tumor
growth at 6 to 12 months (orange), and adverse events (gray), where we were not able to establish a PDX because of reasons other than tumor take (this analysis
excludes uveal primary samples).
(C) Take rate of cutaneous melanoma-derived tissue.
(D) Time to palpable for all FNA, core, and excisional biopsy patient samples.
(E) Tumor growth rate comparison of FNA, core, and biopsies. Growth was calculated as tumor volume per weeks.
(F) Fresh tumor biopsies (MP0) or PDX after MP1 from three patients were prepared as cell suspensions (leucocytes and endothelial cells excluded) and injected
s.c. into NSG mice at the indicated cell numbers.
(G) Single-cell suspension was prepared as before and sorted for CD271 marker. CD271+ and negative cells were injected at indicated cell numbers.
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Krepler et al. [2016]) and 44 progressed on BRAF/MEK inhibitor
combination therapy. We collected 190 samples from patients
with immune checkpoint inhibitor therapy (anti-CTLA4 and/or
anti-PD-1). These did not cluster to any mutational subgroup.
We established PDX from patients progressed on both targeted
and immune therapy (25 sequentially and 17 with BRAF inhibitor/
PD-1 blockade combination therapy) (Figure 3A; Data S2).
The reverse-phase protein array (RPPA) platform quantified
300 proteins and phosphorylated proteins. These profiles are
a useful complementary analysis to genetic sequencing (Krepler
et al., 2016) and are available for 113 PDX models, while others
are in progress (Figure 3A; Data S3).
PDX-Derived Cell Lines
We have established cell lines from 24 PDX tumors with a focus
on targeted therapy resistant and brain metastasis samples
(Figure 3A). These are added to the 112 cell lines of the ‘‘Wistar
Melanoma’’ collection (https://www.wistar.org/lab/meenhard-
herlyn-dvm-dsc/page/melanoma-cell-lines-0). As these PDX-
derived cell lines included 10 derived from targeted therapy-
resistant samples, the mutational distribution is biased for
BRAF hotspot (71%). Further, the cell lines include 7 from brain
metastasis, 2 acral melanoma (WM4324: V600E, WM4235:
Q61R), and 1 mucosal (WM4173: WT/WT).
PDX from Patients Treated with Checkpoint Inhibitors
We established 190 PDX from 140 immune checkpoint blockade
therapy patients. The best response was complete response in
7 patients, partial response in 26, mixed response in 5, stable
disease in 10, and progressive disease in 59 patients. Response
data could not be obtained in 33 patients. Forty-three patients
received only anti-CTLA4, and 50 received only anti-PD-1; 41
patients received both therapies sequentially and 6 as a combi-
nation therapy. All patient samples were collected before, on-, or
Figure 2. Demographics of Patient Samples
Used to Generate PDX
(A) Age of patient at time of biopsy in 10-year in-
crements.
(B) Gender of patient.
(C) Primary tumor type.
(D) Site of tissue biopsy categorized into primary
melanoma, subcutaneous metastasis (SQ), lymph
node (LN) metastasis, distant metastasis to organs
(distant met), and brain metastasis (brain).
(E) Targeted kinase or immune checkpoint inhibitor
therapies the patient had received before or during
the biopsy. Samples without available data were
excluded from the analysis.
after immune therapy with 16 patients
matched before and on or after therapy
(Figure 3B).
PDX from Targeted Therapy-
Resistant Patients
We collected 57 biopsies from 47 patients
after progression on BRAF or BRAF and
MEK combination targeted kinase inhibi-
tor therapy (either still on or shortly after end of therapy) (Fig-
ure 3C). After initial establishment and expansion as PDX, the
tumor-graft-bearing animals were continuously dosed with
BRAF inhibitor (PLX4720) or BRAF/MEK inhibitor (PLX4720/
PD-0325901) combination diet corresponding to the type of ther-
apy received by the patient (Krepler et al., 2016). Targeted
sequencing of resistant PDX tumors using our 108-gene panel
(Garman et al., 2017) confirmed a BRAFV600 hotspot mutation
in all but two of the models. These two PDX models were estab-
lished from patients with clinical BRAFV600E-positive tumors.
However, the patient material tested for WM4323 was the
primary cutaneous melanoma diagnostic biopsy accessioned
5 years prior to the specimen sent for PDX. This was done via
pyrosequencing of codons 595 and 600 of exon 15 of the
BRAF gene. The patient material tested for WM4352 was a met-
astatic lymph node accessioned 7 months prior to the specimen
sent for PDX. This was done via NGS panel of 50 genes
including, for BRAF, codons 439–473 of exon 11, and codons
581–611 of exon 15.
Several mechanisms of resistance were revealed by targeted
sequencing. We found concomitant RAS (n = 7/47 patients) and
MAP2K1/2 (n = 9/47 patients)mutations. These deleteriousmuta-
tions were mutually exclusive and have been reported previously
as activating mutations conferring resistance to BRAF inhibition
(Emery et al., 2009; Nazarian et al., 2010). BRAF high-level ampli-
fication (>5) in 4 patients andMET high-level amplification (> 5) in
3 patients were exclusive of each other and RAS- and MAP2K-
activating mutations (Shi et al., 2014). PDX from 15 patients
had alterations in the PI3K signaling pathway (13 PTEN deletion,
3 deleterious PTEN mutation, 5 likely deleterious PTENmutation,
1 deleterious PIK3CAmutation), although thesewere notmutually
exclusive with the other genomic changes observed.
Patient-matched PDX from before start and after progression
on targeted therapy were generated from 7 patients. Of these,
1956 Cell Reports 21, 1953–1967, November 14, 2017
Figure 3. Overview of PDX Collection, Immune Therapy, Targeted-Therapy-Resistant Samples, and Brain-Metastasis-Derived Subsets
(A) All PDXand live frozen tissue samples sortedbydrivermutations and therapy receivedby thepatients.Drivermutations aredarkblue for hotspot and light blue for
non-hotspot mutations. PDX from patients progressed on targeted therapies are shades of purple; patients treated with immune checkpoint inhibitors are green:
sequential, combination CTLA4+PD-1 (IT combo) or combination with BRAF inhibition (TT/IT combo). Red indicates in vivo growth, presence of RPPA data, or a
corresponding cell line. Samples that spontaneously metastasize to lungs in mice are red; yellow indicates no lung metastasis; and white indicates not assessed.
(B) Patients were treated with CTLA4 or PD-1 blocking therapy before, during, or after biopsy. Combination therapies are indicated. PDX are sorted by best
response in the patients. Additional PDX with unknown response are not shown.
(C) Genetic data of BRAF (BR) and BRAF/MEK (CR) inhibitor-resistant PDX. Deleterious and likely deleterious mutations, homozygous loss, and high copy
number gains (>5) are shown. Numbering after dash (1–4) indicates additional PDX available from the same patient. Asterisks indicate resistant PDXwith available
patient-matched pre-therapy-derived PDX.
(legend continued on next page)
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two (WM4298, WM4351) acquired NRAS mutations on dab-
rafenib/trametinib (D/T) combination therapy and progressed
after 406 and 161 days, respectively. WM3901 was established
from a solitary progressing (>10%) s.c. metastasis after
480 days on D/T combination therapy and had acquired a
BRAF amplification. WM4264 had PFS of 120 days and an ac-
quired MEK2K61E heterozygous mutation in the relapse PDX.
Although a variant of unknown significance per our algorithm
(Garman et al., 2017), because of the location and glutamic
acid change, this might be a phosphomimetic-activating muta-
tion (Villanueva et al., 2013). WM4070 PDX were established
from the patient with the shortest PFS (60 days), and we found
a pre-existing MEK1 mutation in both pre-and post-therapy
PDX. The remaining two models (WM4276, WM4237) had pre-
existing loss of PTEN and amplification of MET, respectively,
as possible contributors to resistance (Figure 3C).
Protein Expression Profiles
RPPA was performed on a total of 118 PDX models in triplicate
and divided between two batches. Set 102 (Data S3) had 184
profiles representing 60 models including one model with corre-
sponding untreated and BRAF inhibitor treated samples. Set 119
(Data S4) had 243 profiles containing 58 models, 23 of which
have corresponding untreated and BRAFi- and/or BRAFi/
MEKi-treated tumor samples. Set 102 assessed 279 phospho-
and total proteins, and set 119 assessed 299 phospho- and total
proteins.
PDX Derived from Brain Metastasis
We collected melanoma brain metastasis (MBM) tissue from 34
neurosurgeries of 28 patients to generate PDXmodels. Targeted
sequencing data are currently available for 20 PDX and RPPA
data for 12 (Figure 3D). Remarkably, four brain metastases
were collected from the same patient (WM4237-1 to -4) at
2- to 4-month intervals. Although the patient had received D/T
combination therapy (best response, stable disease) after the
first surgery, and had received anti PD-1 therapy during the
last two surgeries, all four PDX had identical mutation profiles
(BRAFV600E RB1N690fs TP53S241). PDX from 7 patients had
BRAF hotspot mutation and from 6 patients NRAS hotspot
mutation. One of these had a co-occurring BRAF non-hotspot
mutation. Another BRAF non-hotspot mutation was co-occur-
ring with an NF1 mutation. Two patients were WT for both
BRAF and NRAS. Interestingly, the samples without BRAF hot-
spot mutation had significantly more concurrent deleterious
and likely deleterious mutations overall. We found PTEN deletion
or deleterious mutation in 4 of 7 patients with BRAF hotspot
mutation which has been shown to be associated with MBM
(Bucheit et al., 2014). On the protein expression level, both
patients with deleterious PTEN mutations had evidence of
PI3K pathway activation by relative increased phospho-AKT
compared to WT PTEN samples.
PDX from Primary or Metastatic Uveal Melanoma
Samples
We implanted 45 uveal primary samples as tumor fragments s.c.
in the interscapular fat-pad of NSG mice with matrigel (Ne´mati
et al., 2010). After follow-up of at least 12 months, we observed
tumor growth in five models, albeit kinetics were slow. Three of
these had mutations in GNAQ or GNA11; one was WT; and
one failed genomic analysis. In contrast, the take rate for meta-
static samples from uveal melanoma patients was comparable
to cutaneous melanoma, and we established four samples as
PDX; one with a GNAQ mutation; and the others are in process.
Availability of PDX Models to the Research Community
A critical component of our PDX platform is its availability
to the research community. Like cell line repositories, PDX
tissue can be frozen and expanded as needed. Thus, we made
a representative pre-selection of 26 ‘‘work horses’’ based on
genetic and clinical criteria (https://www.horizondiscovery.
com/patient-derived-xenograft/melanoma-pdx) (Data S2). All
other models are available on request, and tissue will be
expanded either at Horizon Discovery (St. Louis, MO, USA) or
at our laboratory.
Spontaneous Metastasis Rate Is Associated with
Mutational Group
When cells from a PDX model were inoculated into a human skin
graft on NSG mice (Li et al., 2015), tumors formed within the hu-
man dermis. These thenmetastasized out of the human graft into
the lungs of host mice as an indicator for distant organ metas-
tasis (Figures 4A–4C). This propensity to invade themouse tissue
and seed distant organs was reflected in the subsequently
observed high rates of spontaneous metastasis in s.c. implanted
PDXmodels. We analyzed lungs of mice at the time of tumor har-
vest (Figure 4D) and found that in 32% of PDXmodels assessed,
more than 80% of the animals had micro- or macro-metastases
(Figure 4E). There was a significant increase in metastatic ability
of BRAF hotspot mutant PDX and a decreased metastatic rate in
triple WT PDX (Figure 4F).
Spontaneous Brain Metastasis Model
An MBM-derived PDX was established as a short-term culture,
transfected with a luciferase reporter and implanted s.c. into
NSG mice. To prolong survival of animals, primary tumor grafts
were surgically removed once established (Figure 4G). We
observed spontaneous metastasis to the mouse brain in 50%
of animals after a latency of 120 days (Figure 4H). Additional
models are in development.
PDX Tumors Resistant to MAPK Inhibitors Have
Increased IGF1R Expression
We assessed expression of a panel of melanoma surface recep-
tors previously described as cancer stem cell markers including
(D) Patient matched pre- and post-therapy PDX models. Progression-free survival of patients treated with BRAF or BRAF/MEK inhibitor (x axis). Columns are
labeled with putative resistance mechanisms.
(E) Genetic profile and therapy received of 22 PDX with available sequencing data out of 31 total brain metastasis PDX. Deleterious and likely deleterious
mutations, homozygous loss, and high copy number gains (>5) are shown. As an indication of PI3K pathway activation status, RPPA levels of phosphorylated AKT
are shown.
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Figure 4. Melanoma PDX Metastasize Spontaneously
(A) Animals were grafted with neonatal foreskin grafts, and melanoma PDX cells were injected into established grafts.
(B) Melanoma lesions formed in the human skin reconstructs.
(C) Melanomas spontaneously metastasized to the mouse lungs from the human skin graft. H&E staining; representative images.
(D) Example of spontaneous micro-metastasis to lung.
(legend continued on next page)
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CD20 (Fang et al., 2005), CD271 (Boiko et al., 2010), and CD133
(Monzani et al., 2007) in two cohorts of therapy naive and resis-
tant PDX. There were no significant differences observed for any
of the markers (data not shown). However, tumors derived from
targeted-therapy-progressed patients had significantly higher
levels of IGF-1R than tumors from therapy naive patients (Fig-
ure 4I). IGF-1R/PI3K signaling has previously been implicated
in conferringmelanoma resistance to BRAF inhibitors (Villanueva
et al., 2010). Interestingly, when the resistant tumor grafts were
grown on continuous BRAFi or BRAF/MEKi combination diet,
the IGF-1R levels returned to baseline (Figure 4I). This phenom-
enonmight indicate the transient nature of tyrosine kinase recep-
tor upregulation and its modulation byMAPK pathway inhibitors.
Predictive Value of PDX for Response to Targeted
Therapies
We selected a PDX from a 55-year-old female patient with met-
astatic melanoma and early relapse to vemurafenib after partial
response using RECIST 1.1 criteria and progression-free survival
of 16 weeks. Lymph node lesions in her right and left axillary re-
gions showed initial on-treatment regression: there was a 70.6%
decrease in the target lesion (i.e., the right axillary node) and a
partial response in the non-target lesion (the left axillary node)
(Figure 5A). An FNA was taken from the left lymph node before
therapy and used to generate a PDX. After in vivo expansion,
tumor-bearing animals were treated with the BRAF inhibitor
PLX4720 alone and in combination with the MEK inhibitor
PD-0325901. Tumors did not respond to BRAF inhibition, but
regressed on BRAF/MEKi combination followed by relapse
(Figure 5B). This was reflected in a reduced proliferation rate in
the combination therapy tumor cells only (Figure 5C).
MEKandPI3KBeta Inhibition as Second-Line Therapy in
BRAF-Inhibitor-Resistant Models
We selected three BRAF-V600E PDX models derived from pa-
tients relapsed on BRAF inhibitor. Two had homozygous PTEN
deletion, and one had an activating NRASQ61K mutation; all
showed activation of both MAPK and PI3K pathways on the pro-
tein level (Krepler et al., 2016). The MEK inhibitor trametinib and
the PI3K beta/delta isoform-specific inhibitor GSK418 (an analog
of GSK2636771 (R.A. Rivero and M.A. Hardwicke, 2014, Cancer
Res., abstract) significantly decreased tumor growth in the two
PDX models with PTEN deletion without evident toxicity (Fig-
ure 5D), but not in the PDX with concurrent BRAF and NRAS
mutation.
ERK and MDM2 Inhibition Is Highly Effective in a
BRAF-Inhibitor-Resistant PDX Model
WM3973 was derived from a patient progressed on vemurafenib
with MAPK pathway reactivation via an activating MAP2K1
(MEK1) mutation as a potential resistance mechanism (Krepler
et al., 2016). Accordingly, this PDX model did not respond to
BRAF inhibition or even to the downstream targeting ERK inhib-
itor BVD-523. We then applied a previously published response
biomarker signature for p53 reactivation (Jeay et al., 2015) to a
cohort of 9 TP53 WT BRAF-inhibitor-resistant PDX models.
The majority, including WM3973, were predicted to be sensi-
tive to MDM2 inhibition (data not shown). The MDM2 inhibitor
CGM097 (Holzer et al., 2015) moderately inhibited WM3973 tu-
mor growth as a single agent, but ERK andMDM2 inhibition syn-
ergized potently to induce stable disease over 6 weeks of dosing
(Figure 5E, left panel).
Typical of the tumor growth heterogeneity seen in PDX exper-
iments, single mice showed a variable response to the combina-
tion therapy (Figure 5E, right panel). Whereas tumors in most an-
imals had stable disease, two tumors showed early relapse, and
two tumors had complete responses at the end of dosing. Both
regrew only after treatment was stopped, confirming that in PDX
models small residual tumors can survive following several
weeks of drug therapy. However, we did not observe any tumors
acquiring resistance while on combination therapy, indicating
that this approach could be explored further using additional
models.
We analyzed protein expression profiles of tumor grafts at the
end of dosing to investigate the heterogenous responses seen
with this therapy. The clusters from unsupervised hierarchical
clustering identified groups that were predominately based on
proteins with a role in proliferation and correlated with tumor
growth rates rather than dosing groups (Figure S1). The BVD-
523 single-agent group whose tumors grew at the same rate
as controls, clustered with the fastest growing tumors in the con-
trol group, indicating that ERK inhibition alone did not widely
change the protein and phosphoprotein levels assessed in
this array. Indeed, there was no inhibition of pERK on RPPA.
However, the BVD-523 single-agent group had the least tumor
growth variability with all tumors progressing rapidly. All tumors
with continued response to combination treatment clustered
in one group, whereas the two tumors with early resistance to
the combination therapy clustered with the CGM single-agent
samples.
Rapid In Vivo Screen for BET Inhibitor Activity in a Broad
PDX Panel
We used the novel BRD4 inhibitor BAY8097 to conduct a rapid
in vivo screen on 20 PDX of diverse mutational profiles. To test
feasibility, we reduced group size from 10 to 3 mice per group.
Like themodel in Figure 3E, we observed significant heterogene-
ity in tumor growth, a problem also encountered in a recently
published study using only one tumor graft/PDX/therapy (Gao
et al., 2015). We found that a subset of models not clustering
into a mutational subgroup showed significant tumor growth
inhibition using BAY8097 as a single agent (Figure 5G).
(E) Percentage of PDX that metastasize to lungs in more than 80% of animals from the s.c. tumor graft at the time point of maximal tumor volume.
(F) Number of PDX with spontaneous lung metastasis compared to main mutational subgroups.
(G) Luciferase-transfected brain metastasis PDX injected s.c.
(H) Spontaneous metastases to the mouse brain were imaged ex vivo after a latency of 120 days after survival surgery.
(I) Percentage of IGF1R-positive cells in PDX from naive patients, from patients progressed on BRAF inhibitor (BR), from patients on BRAF inhibitor, or from
patients on BRAF/MEKi combination diet.
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Validation of Increased Onco-Metabolites in PDX with
IDH1 Mutation
We identified 8 PDX with the canonical IDH1 mutation R132C.
Only one melanoma cell line with very slow growth kinetics has
been described in the literature (Lopez et al., 2010). Indeed, we
were unsuccessful in establishing cell lines from these patient
samples (data not shown). We tested levels of the D-2-hydroxy-
glutarate (2-HG) onco-metabolite (Mondesir et al., 2016) and
confirmed buildup to very high levels as compared to WT in
PDX tissue (Figure 5H).
Figure 5. PDX Models in Pre-clinical Trials
(A) Computed tomography scans of patient with early relapse on vemurafenib and whose tumor was used to generate a PDX from a pre-therapy LN metastasis.
Arrow indicates the lymph node metastasis biopsied, imaged before and 3 months on vemurafenib therapy.
(B) The PDX-bearingmice were fed a chemical additive diet containing PLX4720 200 ppm as single agent or in combination with PD-0325901 7 ppm (PLX+MEKi).
The combination diet inhibited the PDX tumors’ growth, followed by early on-therapy relapse.
(C) Ki67 staining indicating actively proliferating cells from tumor grafts on indicated treatments.
(D) Two PDX models from patients relapsed on BRAF inhibition (n = 10/group) were treated with chemical addictive diet containing the MEK inhibitor trametinib
2.1 ppm (Tram), the PI3K beta inhibitor GSK231418 214.3 ppm (GSK418), or the combination of both. An asterisk indicates the combination significantly inhibited
tumor growth over single agents in both models.
(E) PDX model from a BRAF-V600E patient relapsed on vemurafenib (PFS 46 weeks, best response stable disease) that had an additional activating MEK
mutation, TP53WT, and a biomarker signature indicating sensitivity to p53 reactivation. PDX tumors (n = 10/ group) were treated with the ERK inhibitor BVD-523
50 mg/kg twice daily oral gavage, the MDM2 inhibitor CGM097 100 mg/kg once daily oral gavage, or the combination of both. (Right panel) Single mouse growth
curves of the BVD-523 + CGM-treated group highlighting the heterogeneity of response in PDXmodels. While most tumors showed stable disease, twomice had
early relapse and two mice had complete responses (CR). Dosing was stopped on day 38 (blue arrow), and the 2 CR mice showed regrowth of residual disease.
(F) 20 PDX of BRAFV600mutant patients (naive and BRAF inhibitor resistant), NRASmutant, and BRAF-WT NRAS-WT (n = 5 models each) were treated with the
BET inhibitor BAY8097 10 mg/kg once daily by oral gavage (orange) or vehicle control (n = 3/group, blue) in a rapid in vivo screen. Although variability within the
PDX models was high, tumor growth velocity was decreased in a subset of models. Response was independent of mutation status.
(G) IDH1 mutant PDX have increased 2-HG onco-metabolite levels in tumor tissue compared to IDH1 WT PDX.
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PDX Can Model Pathway Adaptation to Targeted Drugs
over Time
To assess the potential of PDX models to mimic acquired drug
resistance, we performed a time-course analysis of response
and acquired resistance to a BRAF inhibitor in a targeted ther-
apy-naive BRAF-V600E PDX. The patient had received BRAF in-
hibitor therapy after the biopsy was taken and initially responded
followed by relapse after 9 months. Although, the patient never
received BRAF/MEK combination therapy, we followed up with
this combination in our PDX model (Figure 6A). The PDX tumors
initially responded to BRAF inhibition with almost complete
tumor regression but relapsed 7 seven weeks; however, when
the same animals were switched over to BRAF/MEK inhibitor
combination, they again responded continuously without
relapse for up to 2.5 months. Tumors from each treatment
were analyzed for protein expression by RPPA in a time-course
manner (Figure 6B; full dataset in Data S5). Protein expression
only changed significantly with the onset of BRAF inhibitor resis-
tance (Figure 6C), and the subsequent change to BRAF/MEK in-
hibitor combination therapy shut down cell proliferation, induced
apoptosis, and led to sustained tumor growth inhibition (Fig-
ure 6D). Thus, PDX models can be used to track changes in tu-
mor cell signaling on the protein level over the course of therapy.
DISCUSSION
Established melanoma cell lines have significant bias toward
BRAF, TP53 mutations, and CDKN2A loss (Garman et al.,
2017) since these adapt well to in vitro growth. The much higher
success rate of PDX regardless of mutational subgroup make
PDX more clinically relevant (Byrne et al., 2017; Townsend
et al., 2016). Several other research groups have established
melanoma PDX models (Einarsdottir et al., 2014; Gao et al.,
2015; Girotti et al., 2016; Kemper et al., 2016; Quintana et al.,
2012). Quintana et al. (2012) established PDX from 25 stage
IIIB/C patients and correlated spontaneous metastasis in the an-
imals with patient outcome. Einarsdottir et al. (2014) established
PDX from 23 patients and predicted targeted therapy responses
in a subset. Gao et al. (2015) employed a 1 3 1 3 1 in vivo trial
design in 277 PDX including 67 melanoma derived, demon-
strating clinical translatability of this approach. Kemper et al.
(2016) established 89 PDX, but focused on BRAF mutant pa-
tients with only 10 NRAS and 6 WT/WT samples. They then
used this platform to identify a novel resistance mechanism to
BRAF inhibition in the form of a duplicated kinase domain. Girotti
et al. (2016) have built a collection of about 90 PDX models, of
which they show 3 deeply characterized examples by following
the development of resistance to targeted therapy over time
using whole-exome sequencing. Together, these studies show
the promise and potential of PDX models in melanoma.
Multiple resistance mechanisms to targeted therapy have
been described and these most often lead to reactivation of
the MAPK pathway or activation of alternative pathways such
as the PI3K signaling pathway (Rizos et al., 2014). Pre-clinical
data by several groups have suggested that combining BRAF/
MEK inhibitors with PI3K/mTOR inhibitors may overcome resis-
tance in BRAF mutant melanomas (Atefi et al., 2011; Greger
et al., 2012; Shannan et al., 2016; Villanueva et al., 2010).
Phase I clinical trials using this combination demonstrated
the safety of this combination approach and some early signs
of clinical activity (Bedard et al., 2015; D. Juric et al., 2014,
J. Clin. Oncol., abstract), and further phase I/II trials are ongoing
(NCT01449058; https://clinicaltrials.gov). On the other hand, a
phase I trial testing the combination of pan-PI3K/mTORC1/2
inhibitor GSK2126458 with trametinib was terminated due to a
lack of tolerability and efficacy (NCT01248858), suggesting
a narrower targeting profile might be advantageous. Thus, our
pre-clinical PDX trial confirmed that combination of a beta iso-
form specific PI3K inhibitor retained synergistic potential with
MEK inhibition but could potentially decrease toxicity.
We included PDX with diverse mutational backgrounds that
were either naive or progressed on targeted therapy in an in vivo
screen of a novel BET inhibitor. Targeting the transcriptional ac-
tivity of cancer cells has emerged recently as a novel strategy
(Filippakopoulos et al., 2010). It is unclear however, which pa-
tients would benefit from these inhibitors and whether it would
be a viable strategy in a clinical setting for melanoma (Segura
et al., 2013). Our PDX collection is large enough to mirror the di-
versity of patients that would be studied in an early-stage clinical
trial at a fraction of the cost and could be beneficial for early-
stage drug screening as well as for the development of bio-
markers. The activity of BET inhibition seen in a subset of PDX
models, although hampered by high heterogeneity, still warrants
further investigation into this class of compounds and use of the
PDX data to identify response biomarkers.
Another strength of our large collection of PDX is the breadth
of coverage including multiple samples with rare mutations,
made possible by large-scale targeted sequencing of PDX
(Garman et al., 2017). IDH1 is a rarely mutated oncogene in mel-
anoma, representing about 6% of driver mutations (Cancer
Genome Atlas, 2015) and has been described as a viable target
in other cancers (Tateishi et al., 2015). Since PDX are a living
resource, we could functionally validate the mutation by assess-
ing the accumulation of the onco-metabolite 2-HG in the tumor
grafts. Thus, these models would be ideal to test inhibitors
of IDH1.
MBM is a common event in late-stage patients and has a poor
prognosis of less than one-year median survival (Staudt et al.,
2010) even with modern systemic therapies (Forschner et al.,
2017). Although current targeted and immune therapies have
Figure 6. Protein Pathway Activation over Time and in Response to MAPK Inhibition
(A–D) WM4007 was generated from a pre-BRAF inhibitor therapy biopsy. (A) PDX growth curves for mice treated with PLX4720 (BRAFi) or PLX4720+PD-0325901
(BRAF/MEKi) diet started at time points indicated by black data points. (B) Protein expression change patterns identified in RPPA data with Kmeans clustering. All
proteins within each cluster are averaged, and SD is shown. Clusters in bold had variation above 0.1 and were analyzed further. (C) Hierarchical clustering of
RPPA data normalized to controls depicting the significant K means clusters along each time point. (D) Ingenuity pathway analysis (IPA) was used to assign
proteins within each cluster into distinct biological processes. (Top axis) The top five significant gene ontology terms within each cluster are displayed with bars.
(Bottom axis) The percentage of each cluster’s proteins found within each biological functional category is displayed with orange dots.
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demonstrated activity in MBM, successful therapy is still a major
challenge and an important area of current investigation (Glitza
Oliva et al., 2017). MBM models are scarce and new therapies
are needed urgently. Thus, we focused our collection efforts
on samples derived fromMBM, and these will provide a valuable
resource to study this challenging to treat and frequently lethal
manifestation of late-stage melanoma.
Although patients can show long-lasting responses to immune
checkpoint blockade, many patients do not respond or acquire
resistance. Clinical studies point toward the importance of the
immune infiltrate in tumors (Chen et al., 2016); however, human
tumor-infiltrating lymphocytes implanted with the initial patient
tumor tissue are lost in PDX propagation. High mutational load
is associated with increased response rates to immune therapies
with neo-antigens the target of immune responses (Peng et al.,
2016). Thus, PDX models from checkpoint inhibitor responders
and non-responders could potentially be valuable tools to study
the role of tumor biology in response to immune therapy, and
we are currently investigating neo-antigens. Our collection of
PDX can be used to study checkpoint inhibitors or other immune
therapies alone or in combination with targeted kinase inhibitors
when employed in humanized mouse models (unpublished
data). In these models, human CD34+ hematopoietic stem cells
are injected to reconstitute human B and T cells in NSG mice
(Rongvaux et al., 2014). Thus, the current limitations of model
could potentially be addressed using humanizedmice andwould
allow PDX models to be at the forefront of immune and targeted
therapy translational research (Sanmamed et al., 2016). These
studies are ongoing.
In summary, we have built a unique and comprehensive
melanoma PDX collection representing the entire spectrum
of this cancer with multiple biological replicates even for rare
subgroups. It is further enhanced through genetic and genomic
analysis in our companion paper (Garman et al., 2017).
EXPERIMENTAL PROCEDURES
Detailed SOPs for all aspects of PDX generation and use are provided in
Data S1.
Patient Sample Processing
Patient samples were collected under institutional review board (IRB)
approval. Tumor samples were processed within 24 hr of biopsy. Samples
were mechanically dissociated and enzymatically digested if necessary.
Tumor tissue was frozen in 10% DMSO and 90% fetal bovine serum
(FBS), if sufficient quantities were available, or implanted directly into NSG
mice. Mice were anesthetized; a small skin incision (5 mm) was made in
the back of the animal; and an s.c. pocket was created. Tumor fragments
were implanted with 100 mL of matrigel, and the incision was closed with a
wound clip.
PDX Maintenance
All animal experiments were performed in accordance with institutional guide-
lines under Wistar IACUC approval. PDX were expanded in NSG mice. Tumor
size was assessed onceweekly by calipermeasurements ([length3width2]/2).
Animals were sacrificed when the tumors reached 1,000 mm3 or when neces-
sary for animal welfare. The larger part of the tumorwas retained as a live tumor
bank, the smaller part was reimplanted at a 1:5 ratio. PDX tumors from patients
progressed on BRAF or BRAF/MEK inhibitor therapy were expanded on
continuous PLX4720 200 ppm or PLX4720 200 ppm + PD-0325901 7 ppm
chemical additive diet (Research Diets, New Brunswick, NJ, USA).
Pre-clinical In Vivo Trials
When tumors reached 200mm3,micewere randomized into treatment groups.
10 animals were assigned to each group in the efficacy studies to account for
variability among tumors, except for the BAY8097 rapid in vivo screen, which
was designed with three animals per group. Tumor size was assessed twice
weekly per caliper measurement, and tumor volume was estimated using the
formula ([length 3 width 3 width]/2). Mice were sacrificed after 2–3 weeks of
treatment. If therapy groups showed tumor regression, dosing was prolonged.
Short Tandem Repeat Profiling
We performed short tandem repeat (STR) profiling on one tumor per mouse
passage (MP) using the AmpFlSTR Identifiler PCR Amplification Kit (Life Tech-
nologies, Carlsbad, CA, USA), which uses loci consistent with all major world-
wide STR standards. Genomic DNA was extracted from patient or xenograft
tumor samples using the DNeasy Blood and Tissue Kit (QIAGEN, Valencia,
CA, USA) in accordance with the manufacturer’s instructions. PCR amplifica-
tion and STR allele separation and sizing were performed by the Wistar
Genomics Facility. Profile interpretation was performed in our lab by matching
the resultant DNA fingerprint to our internal database, which includes over
1,000 fingerprints and is available on our website (https://www.wistar.org/
lab/meenhard-herlyn-dvm-dsc/page/melanoma-cell-str-profiles). DNA finger-
printing was matched to normal blood DNA, if available, to confirm the identity
of the samples.
Massively Parallel Sequencing
DNA from patients and/or PDX were characterized by massively parallel
sequencing using a custom-designed 108-gene targeted panel. Results
were annotated for mutations, insertions and deletions, and copy number
changes. A detailed description of the methodology and analysis is provided
in Garman et al. (2017). Briefly, DNA was purified (DNeasy Blood & Tissue
Kit); 500 ng of genomic DNA was sheared randomly into 200-bp fragments;
and sheared DNA was A-tailed and ligated with adaptor-embedded indexes
using the NEBNext UltraTM DNA Library Prep Kit for Illumina (New England
BioLabs, Ipswich, MA, USA). Samples were equimolarly pooled prior to cap-
ture with a 2.2Mbp SureSelectXT Custom Target Enrichment Kit (Agilent Tech-
nologies, Santa Clara, CA, USA) targeting 108 genes previously implicated in
melanomagenesis. Paired-end (23 100 bp) sequencing was performed on the
HiSeqTM 2000 Sequencing System (Illumina, San Diego, CA, USA).
To account for mouse DNA contamination, previously unreported variants
with an allelic fraction of less than 0.15 were filtered out of the analysis.
Foreskin Grafting Procedure
Prepared rectangles of about 1.53 2 cm foreskin were placed on skin defects
on the back of a mouse with the panniculus canosum remaining intact.
The panniculus canosum was needed to help vascularize the graft. The fore-
skin graft was then secured in situ using Tegaderm (3M, St. Paul, MN, USA).
After 10 days, the dressing was removed, and the graft was fully healed in
5–6 weeks.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections of xenograft tumors were
cut into 4-mm sections, deparaffinized in xylene, rinsed in ethanol, and rehy-
drated. Then the tissues were stained with the Ki-67 mouse clone MiB-1
(Dako, Carpinteria, CA, USA; catalog no. M7240).
Flow Cytometry Staining
Tumors were analyzed after mechanical dissociation followed by filtration and
red blood cell lysis. For surface staining, cells were incubated at 4C for 30min
with anti-human PeCy7 CD146 (M-CAM), anti-mouse FITC- CD45, H2Kb, and
H2Kd, and anti-human PE IGFR1 from BD Biosciences (San Jose, CA). Stain-
ing was performed in the presence of LIVE/DEAD Fixable Dead Cell Stains (Life
Technologies). After dead cells and mouse cell exclusion, the percentages of
double-positive CD146 and IGF1R cells were reported.
RPPA
The samples were prepared as previously described (Krepler et al., 2016).
RPPAwas performed by theMDAnderson Center RPPA core facility (Houston,
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TX, USA) as previously described (Tibes et al., 2006). Unsupervised hierar-
chical clustering using centered correlation and complete linkage was per-
formed on normalized log2 median-centered protein values using Cluster
(v.3.0) software (http://bonsai.hgc.jp/mdehoon/software/cluster/software.
htm#ctv). Results were visualized using Java TreeView (v.3.0) software
(http://jtreeview.sourceforge.net).
For WM4007 time-course analysis, normalized log2 values were median
centered to the average of the untreated controls. The three tumors from
each time point were averaged. K means clustering using Euclidean distance
measure on 10 clusters (identified in unsupervised hierarchical clustering) run
for 100 iterations was performed using Cluster (v.3.0) and visualized with Java
TreeView. Clusters with variance greater than 0.10 across the time points
were selected for gene ontology analysis using ingenuity pathway analysis
(QIAGEN) for biological processes.
Statistical Analysis
The scatterplots with mean of multiple mice’s tumor growth rates were re-
ported by FNA, core, and excisional biopsy patient samples or by patient’s
sample. Shapiro normality tests were used to examine the distribution of
studied variables. Non-parametricMann-Whitney tests were used for between
specific gene mutant group comparison. Linear mixed-effects models were
used to test the difference of the tumor growth trends among treatment
groups.
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